NeoChord Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • NeoChord's estimated annual revenue is currently $2.5M per year.(i)
  • NeoChord's estimated revenue per employee is $98,000

Employee Data

  • NeoChord has 26 Employees.(i)
  • NeoChord grew their employee count by 4% last year.

NeoChord's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
CEOReveal Email/Phone
3
CFOReveal Email/Phone
4
Chief Operating OfficerReveal Email/Phone
5
Chief Operating OfficerReveal Email/Phone
6
VP, Clinical AffairsReveal Email/Phone
7
Chief Technology OfficerReveal Email/Phone
8
Director, Business OperationsReveal Email/Phone
9
Chief Commercial OfficerReveal Email/Phone
10
Office ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.4M48-35%N/AN/A
#2
$25.3M164-5%N/AN/A
#3
$2.2M225%N/AN/A
#4
$4.9M4621%$1.7MN/A
#5
$6.8M56-25%$4.1MN/A
#6
$3.9M350%N/AN/A
#7
$28.7M191-9%$1.1BN/A
#8
$0.4M6-25%N/AN/A
#9
$2.5M264%N/AN/A
#10
$1.5M18-40%N/AN/A
Add Company

What Is NeoChord?

NeoChord is a privately held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, received CE market clearance in December 2012.

keywords:N/A

N/A

Total Funding

26

Number of Employees

$2.5M

Revenue (est)

4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

NeoChord News

2022-04-20 - Cardiac Restoration Systems Market Size, Scope And Outlook ...

... Scope And Outlook | Abbott Laboratories, BioVentrix Inc., Edwards Lifesciences Corp., CryoLife Inc., Xeltis AG, NeoChord Inc.

2022-04-20 - Transcatheter Mitral Valve Replacement Market Size, Scope ...

... Edward Lifesciences Incorporation, Biotronik SE & Co. KG, Micro Interventional Devices, Colibri Heart Valve, Llc., Neochord Inc.

2022-03-22 - NeoChord Appoints Martin B. Leon, MD as Executive Chair

... Leon, M.D. as Executive Chair of the U.S. Early Feasibility Study of the NeoChord Transcatheter NeXuS System. March 14, 2022 09:15 ET | Source: NeoChord...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.3M260%N/A
#2
$1.9M27-7%N/A
#3
$2.3M27-10%N/A
#4
$5.4M300%N/A
#5
$4.1M317%N/A